Supplementary Figures S1-S12 from UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S1. Biochemical data for UM-164 and dasatinib. Supplementary Figure S2. Western blots showing the expression of P-Src, P-EGFR and P-p38MAPK in selected TNBC cell lines. Supplementary Figure S3. UM-164 is a dual c-Src/p38 kinase inhibitor in TNBC cell lysate. Supplementary Figure S4. Signaling pathway analysis of SUM 149 cells when treated with dasatinib or UM-164 at their IC50 values (630 nM and 230 nM, respectively). Supplementary Figure S5. Effect on cell invasion of dasatinib alone and dasatinib plus a p38MAPK inhibitor, BIRB-796. Supplementary Figure S6. Effect of dasatinib alone or in combination with p38MAPK inhibitors on the level of P-EGFR/Tyr1068 and P-p38MAPK. Supplementary Figure S7. UM-164 is cytostatic and does not induce apoptosis. Supplementary Figure S8. Histopathology of major organ systems from mice treated with 140 mg/kg UM-164 for 5 days and necropsied. Supplementary Figure S9. In vivo efficacy of UM-164 compared to dasatinib in MDA-MB 231 xenografts. Supplementary Figure S10. Inhibition of p-Src in MDA-MB 468 cells by UM-164 and dasatinib. Supplementary Figure S11. Effect of UM-164, dasatinib alone and in combination with BIRB-796 in spheroid culture. Supplementary Figure S12. Wetsern blot from the UM-164 treated tumor tissues showing expression of P-38MAPK, P-EGFR and P-Src.
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362397046